June 17, 2008
PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
BOSTON, June 17 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global biopharmaceutical services provider, today announced that it is expanding its clinical pharmacology capabilities in the Central Nervous System (CNS) therapeutic area. PAREXEL is enhancing existing services in early phase clinical development by adding pain modeling capabilities and combining traditional pharmacodynamic methods with relevant biomarkers, which are surrogate endpoints used to determine safety and efficacy signals.
"CNS diseases, which are reported to account for one third of the world's disease burden, include neurodegenerative diseases such as Alzheimer's and conditions characterized by chronic pain," said Michelle Middle, MB, ChB, Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. "Our global team of clinical pharmacology experts with in-depth CNS expertise applies various methodologies and biomarkers to help clients make earlier and more effective decisions regarding CNS treatments, and advance this important and growing area of research."
PAREXEL's dedicated clinical pharmacology services directed at alleviation of pain and related symptoms use neuroscience biomarkers to enhance exploration of safety and efficacy and pharmacokinetic analysis. This expanded approach for a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies provides greater information about CNS treatments in early phase development. This expertise is aided by the ability to conduct studies with healthy volunteer and patient populations in a time-efficient manner.
PAREXEL, which is a top provider of expertise-based early phase development services from First in Man to Proof of Concept, utilizes strategic locations, state-of-the-art technology, and highly qualified and experienced personnel to optimize time and cost savings for clients. PAREXEL's clinical pharmacology business has more than 550 beds, among the largest capacities worldwide. The Company's Clinical Pharmacology Research Units are located in Baltimore, Maryland, and in Los Angeles and San Diego, California in the United States; London, United Kingdom; Berlin, Germany; and Bloemfontein and George, South Africa. PAREXEL also provides early clinical development programs through a joint venture arrangement with Synchron Research based in India.
For more information about PAREXEL's international clinical pharmacology capabilities, visit: http://www.parexel.com/early_phase.html.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit http://www.parexel.com/.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes,""anticipates,""plans,""expects,""intends,""appears,""estimates,""projects,""targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Jennifer Baird, Senior Director of Public Relations PAREXEL International Tel: +781-434-4409 Email: [email protected] Rebecca Passo SHIFT Communications Tel: +617-779-1817 Email: [email protected]
PAREXEL International Corporation
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXELInternational Corporation, +1-781-434-4409, [email protected]; orRebecca Passo of SHIFT Communications, +1-617-779-1817, [email protected]
Web site: http://www.parexel.com/http://www.parexel.com/early_phase.html